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| INTRODUCTION
Diabetes mellitus (DM) is associated with a high prevalence of atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease, ischaemic stroke and peripheral arterial disease, and ASCVD is the main cause of mortality and morbidity among those with DM. [1] [2] [3] Furthermore, individuals with both DM and ASCVD represent a particularly high-risk group, with a higher risk of further ASCVD events compared with individuals with ASCVD but without DM. [4] [5] [6] International guidelines for ASCVD risk management place individuals with DM and ASCVD in the highest risk category and recommend treatment with maximally tolerated statin therapy to reduce levels of low-density lipoprotein cholesterol (LDL-C), thereby reducing ASCVD risk. [7] [8] [9] [10] This is supported by data from randomized clinical trials and meta-analyses showing that treatment with statins reduces LDL-C levels and ASCVD risk in individuals with DM. [11] [12] [13] DM is commonly associated with diabetic dyslipidaemia, including elevated triglycerides and reduced levels of high-density lipoprotein cholesterol (HDL-C), and with an increased number of small dense LDL particles and apolipoprotein (apo) B-containing particles, which is thought to contribute to the increased risk level associated with DM. 3, 14 Because of this, some guidelines have suggested using non-HDL-C, representative of the sum total of all atherogenic cholesterol-containing particles, as an alternative or secondary treatment target for LDL-C. 8, 9, 15 However, despite recent increases in the use of high-intensity statin therapy in practice, recent evidence indicates that many individuals with ASCVD and/or DM are not achieving LDL-C and non-HDL-C goals. 16 Further reduction in LDL-C and ASCVD events has been observed in individuals with DM and ASCVD when non-statin therapies, ezetimibe 17 or the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab, 18 were added to statin therapy, compared with statins alone. The proportion of participants in these trials who experienced adverse events was comparable with that of controls. Based on these data, guidelines have been updated and now propose that adding ezetimibe and/or a PCSK9 inhibitor should be considered if the individual does not attain sufficient LDL-C reduction with maximally tolerated statins alone, for example, if they have insufficient response to statin therapy or are unable to tolerate high or any doses of statins. [7] [8] [9] [10] 15 Alirocumab is a PCSK9 inhibitor that signficantly reduced LDL-C and other atherogenic lipid parameters in participants with hypercholesterolaemia in Phase 3 ODYSSEY trials, [19] [20] [21] [22] [23] [24] [25] [26] including dedicated trials involving individuals with DM who were receiving insulin therapy 27 or with mixed dyslipidaemia, 28 with a safety profile comparable to controls. Alirocumab has also been demonstrated to reduce major adverse cardiovascular events vs placebo in patients with recent acute coronary syndrome in the ODYSSEY OUTCOMES trial. 29 Subgroup analyses have suggested similar efficacy and tolerability of alirocumab in individuals with and without DM. 26, [30] [31] [32] [33] However, it is important to examine the effects of alirocumab in the specific subgroup of individuals with both DM and ASCVD who are at particularly high risk and may benefit from additional lipid-lowering therapy beyond a statin. [7] [8] [9] [10] 15 This post-hoc analysis used pooled data from 9 ODYSSEY Phase 3 trials to evaluate the efficacy and safety of alirocumab in individuals with both DM and ASCVD.
2 | METHODS
| Study designs and participants
This post-hoc pooled analysis included individuals with a medical his- For all but one of the trials included in this analysis, eligible participants with a history of ASCVD were required to have LDL-C levels ≥70 mg/dL at screening; in one trial (HIGH FH), eligible individuals had heterozygous familial hypercholesterolaemia with LDL-C levels ≥160 mg/dL at screening. ASCVD was defined as coronary heart disease, ischaemic stroke or peripheral arterial disease. 34 Coronary heart disease included acute/silent myocardial infarction, unstable angina, prior coronary revascularization procedures and other clinically significant coronary heart disease.
In seven trials, alirocumab was administered at a dosage of 75 mg 
| Analysis pools
For analysis of baseline characteristics and lipid efficacy, data from the nine trials were pooled based on alirocumab dosage, control treatment (placebo or ezetimibe) and whether background statin was used: 
| Statistical analyses
Data were analysed using the same statistical approaches as those used for the primary trial analyses. 26 Efficacy was analysed using an intent-to-treat (ITT) approach, including all patients with a baseline and at least one post-baseline LDL-C value, regardless of adherence to treatment, in pools as described above. Least-squares mean lipid values were derived from a mixed-effects model with repeated measures for lipids assumed to follow a normal distribution, and adjusted mean values were calculated from a multiple imputation, followed by robust regressions for lipids not following a normal distribution (ie, Lp(a) and triglycerides) as described previously. 26 The proportion of individuals achieving an LDL-C level < 70 or < 55 mg/dL was analysed using a modified ITT approach, including only on-treatment lipid values, using multiple imputation followed by a logistic regression.
LDL-C < 55 mg/dL is a goal not previously specified for the ODYS-SEY trials but is assessed here following recent guideline updates from the American Association of Clinical Endocrinologists. 9 Descriptive statistics only were used for baseline and safety analyses; no formal statistical inference was planned in the original study protocols. The effects of treatment on glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) are presented for the placebo-and ezetimibecontrolled pools using descriptive statistics and graphs during the treatment period (ie, up to 21 days after the last injection). Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina).
3 | RESULTS
| Baseline characteristics
A total of 984 participants with DM and ASCVD from 9 ODYSSEY Phase 3 clinical trials were included in the analysis. Most had Type 2 DM (n = 969, 98.5%), with few having Type 1 DM (n = 15, 1.5%).
The most common type of ASCVD was coronary heart disease (85%-100% of patients across the groups); most individuals (83%-94%) had hypertension ( Table 1) . Baseline characteristics were generally well balanced between alirocumab and control groups within the pools of studies using background statins (Table 1) . However, there was more variability between the alirocumab and ezetimibe groups in the pool with no background statin; for example, mean baseline LDL-C levels were 157.6 and 194.4 mg/dL, and mean age was 70.3 and 63.0 years, with alirocumab and ezetimibe, respectively. The number of patients in this pool (one study) was relatively small (n = 23 for alirocumab and n = 12 for ezetimibe). Mean baseline LDL-C, non-HDL-C, apoB and triglyceride levels overall were highest in the pool with no background statin ( Table 1) . Figure 2C ). Moderate increases in HDL-C and moderate reductions in triglycerides were also observed with alirocumab, which were significant vs placebo, but not vs ezetimibe ( Figure S5 ).
| Efficacy
HbA1c levels were stable up to 78 weeks in both alirocumab and placebo arms in the placebo-controlled pool of studies ( Figure 3A ). In the ezetimibe-controlled pool, stable HbA1c levels were maintained up to Week 104 in both alirocumab and ezetimibe arms ( Figure 3B ).
Similar trends were seen in FPG (Figures 3C,D) . In addition, stability in HbA1c and FPG levels with alirocumab and control was seen in all patients, irrespective of insulin use ( Figure S6 ).
| Safety
Overall safety was generally similar between alirocumab and control groups in the placebo-and ezetimibe-controlled pools ( Table 2) . Myalgia and other muscle-related TEAEs occurred in <5% of alirocumab-treated patients, and occurred with a similar frequency in the control groups (Table 2) . Injection-site reactions were reported by 5.0% and 2.7% of alirocumab-and placebo-treated patients in the pool of placebo-controlled studies, and by 2.5% and 0.8% of alirocumab and ezetimibe recipients in the pool of ezetimibe-controlled studies; these events were mostly mild and rarely led to treatment discontinuation (Table 2) . closely reflect the true number of atherogenic particles compared with LDL-C. 37, 38 Alirocumab also produced significant reductions in Lp(a), which has been proposed to be an independent cardiovascular risk factor; however, other commonly used lipid-lowering strategies such as statins or ezetimibe have little or no effect on Lp(a). 39 The and previous sub-analyses that revealed no effect of alirocumab on glycaemic parameters 31, 33, 45 or no increase in new-onset DM compared with controls. 45 Abbreviations: ASCVD, atherosclerotic cardiovascular disease; DM, diabetes mellitus; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
| DISCUSSION
a Accidental or intentional administration of study drug at a frequency higher than that allowed by study protocol, if associated with an adverse event.
b Local injection-site reactions were graded by severity and were characterized by related signs and symptoms such as (but not limited to) redness and pain. Severity was highest if an individual experienced several local injection site reactions.
acute coronary syndrome, using alirocumab vs placebo, with exposure for up to 5 years (median exposure, 2.8 years). This analysis is limited by its post-hoc nature and by the non-randomized nature of the subgroups. There were relatively few individuals in the pool with no background statin therapy (ie, the ALTERNATIVE study), which probably contributes to some discrepancies that were observed in this pool, including imbalances in baseline LDL-C between alirocumab and ezetimibe groups, and an observed 4% increase in LDL-C from baseline in the ezetimibe group; in the primary trial, ALTERNATIVE, LDL-C reductions from baseline to Week 24 were 45.0% with alirocumab and 14.6% with ezetimibe. 25 The analysis of glycaemic parameters is limited by the duration of the trials, the longest follow-up being 104 weeks. None of the studies included in this analysis was prospectively designed or powered for analysis of the effect of alirocumab on cardiovascular events, which was assessed in the ODYSSEY OUTCOMES study, 29 
